V
Vaxcyte
Developing superior and novel vaccines designed to treat some of the most common and deadly infectious diseases
About Vaxcyte
Vaxcyte is a biotechnology startup that focuses on the development of vaccines to combat bacterial infections. Their primary target is diseases such as invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. These diseases pose a significant threat to children and adults at risk worldwide. Vaxcyte's business operates in the global healthcare market, specifically in the vaccine sector.
Their business model revolves around the development and commercialization of broad-spectrum vaccines. They generate revenue through the sale of these vaccines once they have been approved for use. Their lead product, VAX-24, is a pneumococcal conjugate vaccine (PCV) that targets 24 different strains of the Streptococcus pneumoniae bacteria. This vaccine has been granted Breakthrough Therapy designation by the FDA for the prevention of invasive pneumococcal disease in adults.
Vaxcyte uses advanced chemistry and modern synthetic techniques, including their proprietary XpressCF™ cell-free protein synthesis platform, to produce these vaccines. This approach allows them to overcome the limitations of traditional cell-based vaccine methods and create vaccines capable of breaking down bacteria's complex defense mechanisms while maintaining their ability to trigger an immune response.
Following VAX-24, Vaxcyte is developing VAX-31, another PCV targeting 31 strains of the bacteria. They also have additional vaccine candidates in preclinical development for Group A Strep, periodontitis, and Shigella.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
Open roles
Vaxcyte in the San Carlos ecosystem
The Vaxcyte office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Abingworth
CTI Life Sciences
Longitude Capital
Roche Venture Fund
Frazier Healthcare Partners
Pivotal Life Sciences
Series B and later6 investors entered at this stage
TPG
Foresite Capital
TPG Growth
MedicxiJanus Henderson Investors
RA Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
Patents
15 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Vaxcyte on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
GPN Vaccines raises $10M to push serotype-independent pneumococcal shot toward Phase 2
Vaxcyte launches $500M stock offering, plus $500M in convertible notes
Vaxcyte's VAX-31 meets all primary endpoints in OPUS-1 Phase 3, supporting BLA plan